CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 63 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $144,209 | +50.1% | 4,849 | -9.1% | 0.09% | +54.4% |
| Q2 2023 | $96,101 | -3.7% | 5,333 | -14.2% | 0.06% | +3.6% |
| Q1 2023 | $99,813 | -36.6% | 6,215 | -27.7% | 0.06% | -32.9% |
| Q4 2022 | $157,343 | +29.0% | 8,598 | +38.1% | 0.08% | +67.3% |
| Q3 2022 | $122,000 | +6.1% | 6,228 | +0.8% | 0.05% | +14.0% |
| Q2 2022 | $115,000 | -17.3% | 6,180 | -2.6% | 0.04% | -30.6% |
| Q1 2022 | $139,000 | -27.2% | 6,346 | -5.6% | 0.06% | -13.9% |
| Q4 2021 | $191,000 | -19.1% | 6,726 | -40.1% | 0.07% | -30.8% |
| Q3 2021 | $236,000 | +5.8% | 11,225 | -5.0% | 0.10% | +13.0% |
| Q2 2021 | $223,000 | -33.2% | 11,810 | -46.0% | 0.09% | -34.8% |
| Q1 2021 | $334,000 | +10.2% | 21,882 | +1.8% | 0.14% | +11.9% |
| Q4 2020 | $303,000 | -0.3% | 21,487 | +10.9% | 0.13% | -20.8% |
| Q3 2020 | $304,000 | -21.2% | 19,371 | -12.1% | 0.16% | -13.1% |
| Q2 2020 | $386,000 | +113.3% | 22,026 | +177.6% | 0.18% | -52.5% |
| Q1 2019 | $181,000 | -33.2% | 7,934 | -12.2% | 0.38% | +737.0% |
| Q4 2018 | $271,000 | – | 9,034 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $76,819,000 | 7.66% |
| RA Capital Management | 1,875,209 | $42,680,000 | 1.84% |
| Perceptive Advisors | 2,587,953 | $58,901,000 | 1.66% |
| EMORY UNIVERSITY | 97,035 | $2,209,000 | 1.55% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $3,817,000 | 1.05% |
| Orbimed Advisors | 1,914,282 | $43,569,000 | 0.67% |
| Opaleye Management Inc. | 73,000 | $1,661,000 | 0.46% |
| Novo Holdings A/S | 135,009 | $3,073,000 | 0.46% |
| Virtus ETF Advisers LLC | 7,934 | $181,000 | 0.38% |
| Eventide Asset Management | 384,000 | $8,740,000 | 0.30% |